Dexcom Unveils Medicare-Covered G7 15-Day CGM and FDA-Approved Smart Basal

Introduction

Dexcom Inc. (NASDAQ: DXCM) is an American medical device company founded in 1999 that designs, manufactures, and distributes continuous glucose monitoring (CGM) systems for individuals with diabetes. Headquartered in San Diego, California, Dexcom operates international research and development (R&D) and production facilities in Mesa, Arizona; Batu Kawan, Malaysia; and Athenry, Ireland.

Corporate Structure and Workforce

With over 10,000 employees worldwide, Dexcom integrates clinical research, device engineering, and software development to support diabetes management. Its core offerings include the Dexcom G6 and G7 CGM systems, Dexcom ONE for replacing finger-stick blood glucose testing, the Share remote-monitoring platform, and Stelo, an over-the-counter glucose biosensor intended for adults not on insulin therapy.

Continuous Glucose Monitoring by Sweet Life

Recent Developments and News

• December 1, 2025: Dexcom launched the G7 15-Day CGM system for users obtaining supplies through durable medical equipment (DME) providers. The sensor has been designed to provide up to 15.5 days of continuous glucose readings; in a clinical study, 73.9 percent of sensors lasted the full duration. Medicare began covering the G7 15-Day under the U.S. Centers for Medicare & Medicaid Services therapeutic CGM category requirements.
• November 2025: The U.S. Food and Drug Administration (FDA) approved Dexcom Smart Basal, the first CGM-integrated basal insulin dosing optimizer for individuals with Type 2 diabetes.
• November 11, 2025: Dexcom announced a partnership with Disabled American Veterans aimed at expanding access to diabetes technologies and educational resources for U.S. veterans.
• November 14, 2025: In observance of World Diabetes Day, Dexcom introduced 16 global diabetes advocates who represent a range of ages and diabetes types, aiming to enhance patient experiences and community engagement.

Financial and Strategic Analysis

On December 1, 2025, DXCM shares closed at $62.84, down 0.99 percent, with a trading volume of 318,942 shares compared to a previous average of 589. The company’s market capitalization is approximately $24.75 billion. Key trailing-twelve-month metrics include:

• Revenue: $4.52 billion
• Net income: $720.7 million
• Diluted earnings per share (EPS): $1.80
• Price/Earnings ratio: 35.26

In its Form 10-Q filed on October 30, 2025 (for the quarter ended September 30), Dexcom reported year-over-year revenue growth and maintained gross margins consistent with prior periods while managing operating expenses to support ongoing R&D investments. As of September 30, 2025, The Vanguard Group held 12.61 percent of Dexcom’s outstanding common stock, indicating significant institutional investment in the company.

Strategic collaborations are a key component of Dexcom’s product roadmap, with partnerships including Verily for G7 sensor development; non-exclusive agreements with Tandem Diabetes Care for G5/G6 integration, Insulet for the Omnipod Horizon, Companion Medical, Livongo, and Welldoc, as well as a November 2024 data-exchange partnership with Oura.

Market Position and Industry Context

Dexcom operates within the expanding global CGM market alongside companies such as Abbott and Medtronic. Its extensive experience in biosensing technology, combined with integrated digital platforms and expanding reimbursement coverage, positions the company to address the increasing demand for real-time glucose data and insulin dosing tools. Manufacturing facilities in North America, Europe, and Asia help mitigate supply-chain risks, while ongoing product enhancements focus on improving sensor wear time, accuracy, and overall user experience.

tl;dr

On December 1, 2025, Dexcom launched the G7 15-Day CGM system with Medicare coverage, and in November the FDA approved its Smart Basal insulin dosing optimizer. Partnerships with Disabled American Veterans and the introduction of global diabetes advocates in mid-November underscored the company’s outreach efforts. Trading volume increased, with shares at $62.84, and institutional ownership remains notable. Future enhancements in sensor-wear duration and integrations are expected to drive growth in the competitive CGM sector.